arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

download Export Data

BridgeBio Oncology Therapeutics, Inc.

BBOT

$4.15 ▼ -0.52 (-11.13%) at close

15 Visible periods

18 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

BridgeBio Oncology Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $332.2M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -14.7% ↘

FCF / Share $-0.55

Trailing P/E —

Price / Book 1.0x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

15-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-42.11M

↓ -90.9% —

FCF / Share Free cash flow per share

$-0.55

↓ -18.4% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
EPS Growth YoY (%)	-24.5% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-870.1% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	N/M	99.9% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	-90.9% Weak ↓ Weak Declining Year-over-year change in net income	-90.9% Weak ↓ Weak Declining Year-over-year change in net income	-97.1% Weak Weak Year-over-year change in net income	-42.8% Weak Weak Year-over-year change in net income	N/M	N/M	—	—	—	—	—	—	—	—	—
FCF Growth YoY (%)	-18.4% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
FCF / Net Income (x)	1.05x Fair → Fair Stable Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.09x Fair → Fair Stable Free cash flow relative to reported net income Optimal: > 1x	1.31x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	1.07x Fair ↓ Fair Declining Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.76x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	2.55x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	—	-0.56x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Return on Invested Capital (%)	-14.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-9.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-8.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-8.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	10.4% Good ↑ Good Improving Return earned on debt + equity capital invested Optimal: > 10%	9.1% Fair ↑ Fair Improving Return earned on debt + equity capital invested Optimal: > 10%	9.7% Fair ↑ Fair Improving Return earned on debt + equity capital invested Optimal: > 10%	9.8% Fair ↑ Fair Improving Return earned on debt + equity capital invested Optimal: > 10%	3.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	1.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—	—	—
Return on Capital (%) (%)	-16.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-11.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-9.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-10.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	-13.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	—	-0.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-0.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—	—
Return on Common Equity (%) (%)	-13.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-187%)	-11.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-175%)	-9.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-163%)	-4.9% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-133%)	9.7% Caution ↓ Caution Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-35%)	11.0% Fair ↑ Fair Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-26%)	11.0% Fair ↑ Fair Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-27%)	9.7% Caution ↑ Caution Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-35%)	-32.6% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-317%)	-34.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-328%)	—	—	—	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Net Debt (USD)	$-54.06M	$-52.66M	$-373.69M	$-408.74M	—	—	$-30.85M	—	—	$-1.84M	—	—	—	—	—

📊 What does each share earn? 5 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Basic EPS, GAAP (USD)	$-705.20	$-526.11	$2.19	$-1.03	$-566.46	$-54.23	$-833.69	$-1.56K	—	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-0.55	—	—	$-0.66	$-0.47	$-48.59	—	—	—	—	—	—	—	—	—
Book Value per Share (USD)	$4.03	$4.65	$5.14	$5.64	$-4.54	$-491.82	—	—	—	—	—	—	—	—	—
Tangible Book Value per Share (USD)	$4.03	$4.65	$5.14	$5.64	$-4.54	$-491.82	—	—	—	—	—	—	—	—	—
Basic Weighted Avg Shares (shares)	80.05M	80,032	—	43.49M	50.20M	406,723	—	11,089	—	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Working Capital (USD)	$190.74M	$223.24M	$397.36M	$440.30M	—	—	$139.11M	—	$2.00M	$2.09M	—	—	—	—	—
Total Equity (USD)	$323.11M	$372.28M	$411.10M	$446.70M	$-227.73M	$-200.03M	$-178.64M	$-159.21M	$-3.37M	$-3.22M	$-63.57K	$-21.88K	$-21.88K	$-21.88K	$-21.88K

📋 What is driving earnings? 3 metrics

Metric	Q2 FY2026 Jun 30, 2026 10-Q ↗	Q1 FY2026 Mar 31, 2026 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Sep 30, 2025 10-Q ↗	Q2 FY2025 Jun 30, 2025 10-Q ↗	Q1 FY2025 Mar 31, 2025 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q3 FY2024 Sep 30, 2024 10-Q ↗	Q2 FY2024 Jun 30, 2024 10-Q ↗	Q1 FY2024 Mar 31, 2024 10-Q ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q3 FY2023 Sep 30, 2023 10-Q ↗	Q2 FY2023 Jun 30, 2023 10-Q ↗	Q1 FY2023 Mar 31, 2023 10-Q ↗	Q4 FY2022 Dec 31, 2022 10-K ↗
Depreciation Expense (USD)	$100.00K	$74.00K	$84.00K	$73.00K	$100.00K	$54.00K	$52.00K	—	—	—	—	—	—	—	—
Net Income, GAAP (USD)	$-42.11M	$-42.11M	$-38.80M	$-22.05M	$-22.05M	$-22.05M	$-19.69M	$-15.44M	$1.10M	$1.10M	—	—	—	—	—
Operating Cash Flow (USD)	$-44.36M	$-35.92M	$-42.23M	$-28.77M	$-23.29M	$-19.60M	$-15.04M	$-39.34M	—	$-618.00K	—	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 4 years · 15 quarters

BridgeBio Oncology Therapeutics, Inc.

Analytical Summary

15-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare BBOT with peers